3 weeks ago
21
MarketBeat
Tue, April 28, 2026 astatine 10:29 AM CDT 9 min read
Key Points
-
Management reaffirmed a commercialization timetable with the Voyager Platform targeted for pre-orders successful precocious 2026, lawsuit installations opening successful aboriginal 2027 and wide availability successful H1 2027, portion expanding its commercialized squad and Iterative Mapping Early Access Program (Baylor College of Medicine named arsenic the archetypal EAP customer).
-
Scientific advancement includes elaborate Tau proteoform insights from collaborations (Buck and Allen Institutes), service-lab assay verification and accrued probe compatibility, positive ongoing alpha-synuclein enactment and a narrowed oncology people database (EGFR, AKT1, P53) with 1 oncology proteoform assay planned for aboriginal entree successful H2 2026.
-
Financially, Q1 operating expenses were $16.1 cardinal (down 14%), currency and investments totaled $143.4 cardinal with Q1 currency pain of $12.8 million, and absorption says the company’s program provides a cash runway done 2027 portion expecting astir $0.5 cardinal successful gross for the twelvemonth (timing shifted later).
-
Interested successful Nautilus Biotechnology, Inc.? Here are 5 stocks we similar better.
Invest successful Gold
Powered by Money.com - Yahoo whitethorn gain committee from the links above.
Nautilus Biotechnology (NASDAQ:NAUT) reported first-quarter 2026 results and highlighted advancement toward its planned commercialization timeline, with absorption emphasizing expanding aboriginal lawsuit engagement, advancing its assay portfolio, and maintaining what it described arsenic a currency runway done 2027.
Commercial build-out and aboriginal entree momentum
Co-founder and CEO Sujal Patel said the institution continues to execute connected milestones it outlined antecedently for 2026, including expanding the Iterative Mapping Early Access Program (EAP) and preparing for a commercialized motorboat targeted for precocious 2026. Patel reiterated anterior expectations that Nautilus plans to unfastened the Voyager Platform for pre-orders successful precocious 2026, with lawsuit installations opening successful aboriginal 2027 and wide availability of broad-scale capabilities successful the archetypal fractional of 2027.
→ Pipelines and Automation: 2 Energy Plays Built for Any Oil Price
Patel said gathering retired the commercialized enactment has been a cardinal precedence for 2026. During the quarter, Nautilus hired Amber Faust arsenic vice president of planetary income and added 2 further income squad members. Patel said the institution believes the squad positions it to prosecute prospective customers up of the commercialized launch.
On the lawsuit front, Patel said inbound involvement successful the Tau assay and customized assay improvement has been “steady and broad-based,” spanning academic, nonprofit, and biopharma organizations. He reiterated that the company’s archetypal named EAP lawsuit is Baylor College of Medicine.
English (CA) · 
English (US) · 
Spanish (MX) ·